AttackMS and ChariotMS: optimizing care from diagnosis to advanced disease скачать в хорошем качестве

AttackMS and ChariotMS: optimizing care from diagnosis to advanced disease

Klaus Schmierer, MB BS, PhD, FRCP, The Blizard Institute, Queen Mary University of London & The Royal London Hospital of Barts Health NHS Trust, London, UK, and Dominic Shadbolt, BA, MSc, Founder of the MSGuide & patient advocate, discuss the ongoing ChariotMS and AttackMS trials, both run by the Queen Mary University of London. The Phase IIb ChariotMS trial is investigating the safety and efficacy of cladribine in protecting upper limb function in patients with advanced MS (EDSS 6.5-8.5). Patients in the advanced stages of MS are often excluded from clinical trials and ChariotMS is the only trial focused entirely on this population. Prof. Schmierer and Mr Shadbolt discuss the importance of maintaining independence for as long as possible in these patients, noting the need for broader conversations about what drives quality of life in the advanced stages of disease. At the other end of the spectrum, the AttackMS study is testing the feasibility of intervention with natalizumab within 14 days of symptom onset. The trial hopes to reduce the delay from diagnosis to treatment of individuals with MS, as well as to provide evidence for the long-term value of an early and aggressive treatment approach. Prof. Schmierer and Mr Shadbolt discuss the inefficiencies holding back MS care in the early stages and the need for robust, evidence-based treatment pathways, advocating for a more urgent and proactive approach to care. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.